Iovance Biotherapeutics Inc.
- BID
4.525
- ASK
4.545
- 13,260 Units2,200 Units
- 07/22, 21:59:48 PM
Sector and Industry
Healthcare, Biopharmaceuticals
Performance (1Y)
69.89%
Market Cap
4.19 Bil.
P/E Ratio
0.00
Dividend Yield
0.00 %
Earnings per Share
-0.97 €
Peer Group
| Company Name | Market Cap | Revenue Last Reported Year | P/E Ratio | Profit Growth 1Y | Last Price | Previous Trading Day Change |
|---|---|---|---|---|---|---|
| Eli Lilly and Company | 864.54 Bil. | 57.78 Bil. | 46.82 | +86.88 % | 0.00 | - |
| Johnson & Johnson | 425.70 Bil. | 83.48 Bil. | 18.82 | +82.71 % | 0.00 | - |
| AbbVie Inc. | 343.94 Bil. | 54.21 Bil. | 96.78 | -5.29 % | 0.00 | - |
| Roche Holding AG | 286.62 Bil. | 65.80 Bil. | 20.72 | +58.45 % | 0.00 | - |
| AstraZeneca PLC | 244.91 Bil. | 52.09 Bil. | 27.55 | +39.41 % | 0.00 | - |
| NOVARTIS AG | 224.76 Bil. | 48.44 Bil. | 18.30 | +12.45 % | 0.00 | - |
| Merck & Co. Inc. | 221.79 Bil. | 57.55 Bil. | 14.46 | +2.25 % | 0.00 | - |
| Novo-Nordisk AS B | 193.52 Bil. | 41.49 Bil. | 14.11 | +1.54 % | 0.00 | - |
| Amgen Inc. | 150.16 Bil. | 32.57 Bil. | 23.01 | +80.77 % | 0.00 | - |
| Gilead Sciences Inc. | 129.70 Bil. | 26.10 Bil. | 18.10 | +1,599.93 % | 0.00 | - |
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE | 4.48 G | 0 Units |
| PRICE DETERMINATION TIME | 07/22/2026 / 09:56:32 PM | |
| DAILY VOLUME (UNITS) | 30 | |
| DAILY HIGH / LOW | 4.85 | 4.48 |
| PREV. DAY'S PRICE | 4.8 | (07/21) |
| CHANGE DAY BEFORE | -0.32 | -6.67 % |
| 52 WEEK HIGH / LOW | 4.85 (07/22) | 1.5542 (11/05) |
Key Figures (in EUR)
| 2023 | 2024 | 2025 | 2026e | 2027e | |
|---|---|---|---|---|---|
EARNINGS PER SHARE | -1.75 | -1.19 | -0.97 | -0.46 | -0.26 |
DIVIDENDS PER SHARE | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
DIVIDEND YIELD IN % | 0.00 % | 0.00 % | 0.00 % | - | - |
DIVIDEND GROWTH IN % | - | - | - | - | - |
PRICE - EARNINGS RATIO | - | - | - | - | - |
PRICE - BOOK RATIO | 3.56 | 3.18 | 1.61 | - | - |
PRICE - SALES RATIO | 1,607.75 | 13.07 | 3.70 | - | - |
PRICE - CASH FLOW RATIO | - | - | - | - | - |
Master Data
| WKN | A2DT49 |
| ISIN | US4622601007 |
| SYMBOL | 2LB |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Equity |
| DENOMINATION | IOVANCE BIOTHERAP.DL-,001 |
| INDEX MEMBERSHIP | - |
| TRADING SEGMENT | - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| TRADING CURRENCY | Euro |
| NOMINAL CURRENCY | US Dollar |
| SETTLEMENT CURRENCY | Euro |
| SECTOR AND INDUSTRY | Healthcare, Biopharmaceuticals |
| NUMBER OF SHARES | 278.93 Mil. |
| MARKET CAPITALISATION | 4.19 Bil. |
Performance overview
| 1W | 1M | 3M | 6M | 1Y | 3Y | 5Y | YTD | |
|---|---|---|---|---|---|---|---|---|
| PERFORMANCE | 8.21 % | 27.09 % | 50.34 % | 96.32 % | 69.89 % | -34.64 % | -77.48 % | 93.23 % |
| HIGH | 4.85 | 4.85 | 4.85 | 4.85 | 4.85 | 16.80 | 23.83 | 4.85 |
| LOW | 3.91 | 3.29 | 2.79 | 1.93 | 1.55 | 1.43 | 1.43 | 1.90 |
Dividende
pro Aktie
IOVANCE BIOTHERAP.DL-,001 does not deliver dividend information
Company profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
Structured products for Iovance Biotherapeutics Inc.
Analyst Rating
Ø-Target Price DistanceNot Available
Current Price
Not AvailableØ-Target Price
Not AvailableAverage ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0
Company Events
No company events available.